A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Incyte Corporation
Akeso
DualityBio Inc.
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
UNICANCER
UNC Lineberger Comprehensive Cancer Center